From: The effect of adding real-world evidence to regulatory submissions on the breadth of population indicated for rare disease medicine treatment by the European Medicines Agency
Evidence type
Total limiter count
Median (IQR: Q1, Q3)
p value
RCTE
37 (28, 43)
0.005
RWE
5 (2, 9)